AstraZeneca PLC CEDEAR

AstraZeneca PLC CEDEAR represents depositary receipts of a global biopharmaceutical company trading in Argentina, allowing local investors to access the economic rights of the underlying foreign shares in local currency. It reflects AstraZeneca’s diversified portfolio across oncology, biopharmaceuticals, and rare disease, anchored by therapies in oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. As a CEDEAR, it facilitates exposure to an internationally listed issuer while providing a vehicle that inherently translates foreign equity performance into the domestic market framework, often incorporating the effects of currency movements. The instrument’s role in the Argentine market is to broaden diversification options beyond local issuers, offering participation in a large-cap, research-driven pharmaceutical leader with an industry-leading pipeline and significant revenue footprint across major healthcare markets. Investors use this CEDEAR to align with long-cycle pharmaceutical innovation, patent-driven cash flows, and global healthcare demand trends, while operating within local settlement and custody infrastructure. Information services track its local performance metrics and peer comparisons to contextualize return drivers within the CEDEAR structure.